



## Scientific letters

**Persistent Isolation of *Staphylococcus aureus* in Mechanically-ventilated Patients: Impact of Host-Pathogen Factors on Outcome**

**Aislamiento persistente de *Staphylococcus aureus* en pacientes sometidos a ventilación mecánica: impacto de factores del huésped y del patógeno en la evolución clínica**

Dear Editor:

Lungs represent the major site of infection in the intensive care unit (ICU).<sup>1</sup> Bacteria recovered from patients undergoing mechanical ventilation (MV) can be part of the resident microbiome so its role as causative agents is still an unresolved issue. Colonization may be persistent even when the clinical symptoms improve.<sup>2</sup> *Staphylococcus aureus* remains a leading cause, both when methicillin susceptible (MSSA) and methicillin-resistant (MRSA). Colonization at ICU admission is a risk factor for developing pneumonia<sup>3,4</sup> but clinical features can range from asymptomatic carriage to severe invasive disease, demonstrating an adaptation and switch in virulence regulation.<sup>5</sup> It is of paramount importance to distinguish colonization from infection and to adequately prescribe antimicrobials.

This was a retrospective and observational study conducted during 2 years (2012–2013). Patients on MV admitted at ICU were selected based on the isolation of *S. aureus* in endotracheal aspirate (ETA). The objectives were to investigate host and microbial factors associated with (1) clinical outcome and (2) persistent isolation despite treatment adjusted to antibiotic susceptibility profile.

ETA and blood cultures were performed when there was clinical suspicion of respiratory tract infection, not systematically. Nasal swabs were obtained to check MRSA carriage. Study was performed according to confidentiality criteria and dissociation of patients' identification data. Data recorded included epidemiological features, presence of comorbidities, Glasgow Coma Scale (GCS), central nervous system (CNS) involvement and severity of illness at admission assessed by Acute Physiology and Chronic Health Evaluation (APACHE)-II.

Patients (all with *S. aureus* ETA culture) were classified into pneumonia, tracheobronchitis or bronchial colonization by expert clinicians according to Clinical Pulmonary Infection Score (CPIS) and radiographic findings.<sup>6</sup> Ventilator associated pneumonia was defined by presence of pulmonary infiltrate and CPIS  $\geq 6$ . Ventilator associated tracheobronchitis was defined when there were fever ( $>38^\circ\text{C}$ ) with no other recognizable cause of purulent secretion and no radiographic signs of new pneumonia. Bronchial colonization was defined in the absence of the aforementioned clinical and radiological features. Data regarding antimicrobial therapy was recorded. Isolation in ETA was defined persistent when it lasted  $\geq 7$  days despite treatment adjusted to susceptibility profile.

Adverse clinical outcome was defined as the development of respiratory complications following definitions from Ferrando et al.,<sup>7</sup> including empyema and septic shock. When after initial improvement, there was need for acute changes in ventilator support to enhance oxygenation, the patient was also considered to have a respiratory complication. Mortality was also recorded. VAP might lead to prolonged ICU length of stay (LOS) and prolonged MV so these parameters were also analyzed to define outcome. Clinical strains were phenotypically characterized by conventional identification and susceptibility testing methods. Antimicrobial treatment prescribed was recorded, and categorized as  $\beta$ -lactams, vancomycin, quinolones and linezolid.

Pearson's chi-square or Fisher test was applied for categorical variables and student's *T* test or ANOVA for numerical variables. Univariate/multivariate analyses were performed. Variables included in multivariate models were selected according to the univariate analysis results. Associations were considered statistically significant if  $p < 0.05$ . Data were analyzed with SPSS v15 (SPSS Inc, Chicago, IL).

During the study period, the global incidence of VAP was 1.61 cases for 1000 days of stay and 2.34 cases for 1000 days of MV. Of the 3012 ETA samples collected, *S. aureus* was isolated in 270 (9%) corresponding to 121 patients classified as: pneumonia (27), tracheobronchitis (45) and bronchial colonization (49). Patients' epidemiological and clinical characteristics and comparisons according to the study group are shown in Table 1. Among the 27 patients with pneumonia diagnosis, chest X-ray results were as follows; 13 cases were unilobar (48.2%), 12 multilobar (44.4%) and 2 had a diffuse pulmonary infiltrate (7.4%). Vascular or traumatic CNS involvement was frequent (42.1%) (previously described risk factor for *S. aureus* colonization). None of the variables allowed a satisfactory distinction between groups.

Initial *S. aureus* isolation was mixed with another microorganism in 35.5% of cases: *Haemophilus influenzae* (16.3%), *Pseudomonas aeruginosa* (14%) and other Gram negative bacilli (58.1%). *P. aeruginosa* was subsequently isolated in 30 patients (24.8%). Twenty-one patients (17.3%) had a positive blood culture, and in 9 cases, the isolated microorganism was *S. aureus* (7.4%).

Respiratory adverse clinical outcome, including mortality related was associated with diagnosis of pneumonia ( $p < 0.001$ ) and staphylococcal bacteraemia ( $p = 0.022$ ) in univariate analysis, and only pneumonia in multivariate ( $p = 0.001$ ; OR: 38.4; IC95%: 4.606–320.165). Interestingly, clinical outcome was similar regardless of cloxacillin resistance. No statistical differences were found when considering ICU LOS, days on MV, age, APACHE-II and GCS.

When considering global mortality, it accounted for 48 patients (39.7%), and 6 cases were staphylococcal infection related. Mortality was significantly associated with the presence of comorbidities ( $p = 0.017$ ), positive *S. aureus* blood culture ( $p = 0.028$ ),

**Table 1**  
Patients epidemiological and clinical characteristics; and comparisons according to the study group considered.

Baseline variables	Colonization (n = 49)	Tracheobronchitis (n = 45)	Pneumonia (n = 27)	p value
Age, y [mean (SD)]	59.7 (15.2)	57.9 (18.3)	60 (17.3)	0.833
Male, %	28 (57.1)	32 (71.1)	17 (63)	0.389
Origin				
Community-acquired	5 (10.4)	6 (13.3)	6 (22.2)	0.172
Nosocomial	43 (89.6)	37 (82.2)	19 (70.4)	
Health-care related	–	2 (4.4)	2 (7.4)	
Presence of any comorbidity	36 (73.5)	33 (73.3)	22 (81.5)	0.713
Diabetes	15 (30.6)	11 (24.4)	7 (25.9)	0.809
Chronic respiratory disease	12 (24.5)	6 (13.3)	4 (14.8)	0.352
Neoplasia	8 (16.3)	9 (20)	6 (22.2)	0.835
Hypertension	20 (40.8)	14 (31.1)	7 (25.9)	0.389
Heart failure	7 (14.3)	8 (17.8)	2 (7.4)	0.500
Renal failure	3 (6.1)	2 (4.4)	–	0.541
Obesity	4 (8.2)	1 (2.2)	–	0.280
Renal transplant/immunosuppression	2 (4.1)	–	3 (11.1)	0.056
Reason for ICU admission				
Medical	33 (67.3)	33 (73.3)	19 (70.4)	0.274
Trauma	4 (8.2)	1 (2.2)	5 (18.5)	
Scheduled surgery	9 (18.4)	9 (20)	3 (11.1)	
Urgent surgery	3 (6.1)	2 (4.4)	0 (0)	
APACHE-II [mean (SD)]	19.8 (8.6)	18.1 (7.9)	17.7 (6.9)	0.489
GLASGOW [mean (SD)]	9.8 (4.6)	10.2 (4.8)	10.4 (5.0)	0.831
CPIS [mean (SD)]	–	3.7 (1.3)	6.8 (1.4)	<0.001*
Vascular or traumatic CNS involvement	19 (38.8)	17 (37.8)	15 (55.6)	0.305
Ischemia	2 (4.1)	1 (2.2)	2 (7.4)	0.635
Bleeding	7 (14.3)	7 (15.6)	4 (14.8)	1
Head trauma	4 (8.2)	2 (4.4)	6 (22.2)	0.061
Other type of CNS involvement <sup>a</sup>	8 (16.3)	8 (17.8)	4 (14.8)	1
ICU length of stay, d [mean (SD)]	23 (22)	26.4 (24)	27.9 (23.1)	0.628
Ventilation, d [mean (SD)]	24 (22.2)	25.9 (23.7)	27.9 (23.2)	0.773
Mechanical ventilation until first <i>S. aureus</i> isolation, d [mean (SD)]	7.3 (8.8)	6.7 (7.3)	5.2 (9)	0.567
Persistent positive culture at 7 days	14 (48.3)	14 (34.1)	11 (40.7)	0.489
Global mortality	21 (42.9)	20 (44.4)	7 (25.9)	0.264
Respiratory complications	1 (7.1)	1 (7.1)	12 (85.7)	<0.001*
Mortality related to the staphylococcal infection	2 (4.1)	–	4 (14.8)	0.018*
Positive <i>S. aureus</i> blood culture	3 (6.1)	2 (4.4)	4 (14.8)	0.324
Previous MRSA carriage	6 (12.2)	2 (4.4)	3 (11.1)	0.360
Cloxacillin resistance	10 (20.4)	7 (15.6)	5 (18.5)	0.870
Mixed first <i>S. aureus</i> isolation	18 (36.7)	14 (31.3)	11 (40.7)	0.693
Consecutive <i>P. aeruginosa</i> isolation	8 (16.3)	16 (35.6)	6 (22.2)	0.092

ICU: intensive care unit, CNS: central nervous system, APACHE-II: Acute Physiology and Chronic Health Evaluation II, CPIS: clinical pulmonary infection score.

<sup>a</sup> Includes anoxic coma, brain neoplasia, epilepsy, encephalopathy and convulsions.

\* *p* was considered significant if <0.05.

previous MRSA carriage ( $p=0.025$ ) and consecutive isolation of *P. aeruginosa* in respiratory sample ( $p=0.052$ ). Patients that died were older ( $p=0.004$ ) and had a higher APACHE index at admission ( $p<0.001$ ).

Selecting the 97 patients that received antimicrobial treatment adjusted to susceptibility profile, persistence at  $\geq 7$  days was documented in 39 cases (40.2%), being 27 MSSA and 12 MRSA. Persistence was frequent independently of the antimicrobial used ( $p=0.036$ ). In the univariate analysis, persistence correlated with: younger age ( $p=0.009$ ), higher CPIS ( $p=0.041$ ), ICU LOS ( $p<0.001$ ) and days on MV ( $p<0.001$ ), cloxacillin resistance ( $p=0.016$ ) and consecutive isolation of *P. aeruginosa* ( $p<0.001$ ). In multivariate only age ( $p=0.003$ ; OR: 0.949; IC 95%: 0.918–0.982) and cloxacillin resistance ( $p=0.003$ ; OR: 7.891; IC 95%: 1.980–31.454) remained significant. Correlation to younger age could be associated to differences in antibiotic pharmacokinetics/pharmacodynamics and inflammatory response. An important aspect is the absence of differences regarding clinical outcome, suggesting that persistence is more related to bacterial adaptation.<sup>2</sup> Potential reasons for persistence could be a limited antimicrobial penetration into lung parenchyma, together with the ability of *S. aureus* to reside intracellularly within host cells and to produce biofilm.<sup>8</sup> The impact of long-term effect of persistent bacterial isolation remains to be elucidated. Persistent isolation was more frequent in MRSA

cases, as expected since antimicrobial treatments such as glycopeptides have poor penetration into alveolar tissues and less intrinsic activity than  $\beta$ -lactams.<sup>9</sup> Still, MSSA isolates were also recovered from persistent cases indicating that cloxacillin resistance or type of antimicrobial are not the only factors intervening in this phenotype. Adequacy of treatment was considered according to the results of in vitro susceptibility testing, but antimicrobial characteristics such as lung penetration, bactericidal/bacteriostatic/intracellular activity were not analyzed.

*S. aureus* has a complex set of virulence factors, with defined implications in severity in community acquired infections but less clear in nosocomial.<sup>10</sup> In recent years, preclinical investigations using monoclonal antibodies against virulence factors have shown promising results.<sup>11</sup> Regulatory systems, such as the accessory gene regulator (*agr*) control virulence factors secretion and its dysfunction has been related to persistent bacteremia and higher mortality. However, we have previously shown that about 80% of isolates from the respiratory tract had a functional *agr* with no correlation with unfavorable outcome.<sup>12</sup>

In summary, our study suggests that persistent *S. aureus* isolation despite adjusted antibiotic treatment is often reported in MV patients, with no correlation with adverse clinical outcome. Although it is more frequent in MRSA cases, it is also reported for MSSA isolates. Thus, in order to optimize antimicrobial treatment,

besides considering positive bacterial culture result it will also be important to identify microbial factors that contribute to virulence in order to initiate a highly-focused personalized therapy.

## Funding

This work has been funded by the project PI13/01418 which is part of “Plan Nacional de I+D+I” and co-funded by ISCIII – Subdirección General de Evaluación and “Fondo Europeo de Desarrollo Regional” (FEDER). This work also received a grant from the Spanish Society of Pneumology and Thoracic Surgery (SEPAR 054/2011). None of the funding sources had a role in study design, collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

## Acknowledgements

We thank Irma Casas for statistical assessment, Isabel Carrasco for her technical assistance and Maisem Laabei for his critical review.

## References

1. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis*. 2016;63:e61–111.
2. Prat C, Lacoma A. Bacteria in the respiratory tract-how to treat? Or do not treat? *International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases*. 2016;51:113–22.
3. Paling FP, Wolkewitz M, Bode LG, Klein Klouwenberg PM, Ong DS, Depuydt P, et al. *Staphylococcus aureus* colonization at ICU admission as a risk factor for developing *S. aureus* ICU pneumonia. *Clin Microbiol Infect*. 2017;23:e9–e14.
4. Paling FP, Troeman DPR, Wolkewitz M, Kalyani R, Prins DR, Weber S, et al. Rationale and design of ASPIRE-ICU: a prospective cohort study on the incidence and predictors of *Staphylococcus aureus* and *Pseudomonas aeruginosa* pneumonia in the ICU. *BMC Infect Dis*. 2017;17:643.
5. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. *Staphylococcus aureus* infections: epidemiology, pathophysiology, clinical manifestations, and management. *Clin Microbiol Rev*. 2015;28:603–61.
6. Zilberberg MD, Shorr AF. Ventilator-associated pneumonia: the clinical pulmonary infection score as a surrogate for diagnostics and outcome. *Clin Infect Dis*. 2010;51:S131–5.
7. Ferrando C, Soro M, Canet J, Unzueta MC, Suarez F, Libroero J, et al. Rationale and study design for an individualized perioperative open lung ventilatory strategy (iPROVE): study protocol for a randomized controlled trial. *Trials*. 2015;16:193.
8. Lacoma A, Cano V, Moranta D, Regueiro V, Dominguez-Villanueva D, Laabei M, et al. Investigating intracellular persistence of *Staphylococcus aureus* within a murine alveolar macrophage cell line. *Virulence*. 2017;8:1761–75.
9. Stulik L, Hudcova J, Craven DE, Nagy G, Nagy E. Low efficacy of antibiotics against *Staphylococcus aureus* airway colonization in ventilated patients. *Clin Infect Dis*. 2017.
10. Aliberti S, Reyes LF, Faverio P, Sotgiu G, Dore S, Rodriguez AH, et al. Global initiative for methicillin-resistant *Staphylococcus aureus* pneumonia (GLIMP): an international, observational cohort study. *Lancet Infect Dis*. 2016;16:1364–76.
11. Sause WE, Buckley PT, Strohl WR, Lynch AS, Torres VJ. Antibody-based biologics and their promise to combat *Staphylococcus aureus* infections. *Trends Pharmacol Sci*. 2016;37:231–41.
12. Gomes-Fernandes M, Laabei M, Pagan N, Hidalgo J, Molinos S, Villar Hernandez R, et al. Accessory gene regulator (Agr) functionality in *Staphylococcus aureus* derived from lower respiratory tract infections. *PLoS ONE*. 2017;12:e0175552.

Alicia Lacoma<sup>a,b</sup>, Meissiner Gomes-Fernandes<sup>a,b,c</sup>,  
Eduard Mesalles<sup>d</sup>, Fernando Arméstar<sup>d</sup>, Cristina Prat<sup>a,b,\*</sup>

<sup>a</sup> Microbiology Department, Hospital Universitari Germans Trias i Pujol, Institut d'Investigació Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain

<sup>b</sup> CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Spain

<sup>c</sup> CAPES Foundation, Ministry of Education of Brazil, Brasília, Brazil

<sup>d</sup> Intensive Care Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain

\* Corresponding author.

E-mail address: crisprat2010@gmail.com (C. Prat).

<https://doi.org/10.1016/j.arbres.2018.05.010>  
0300-2896/

© 2018 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

## Presentación radiológica atípica de un adenocarcinoma de pulmón



### An Atypical Radiological Presentation of Lung Adenocarcinoma

Estimado Director:

El adenocarcinoma de pulmón tiene presentaciones clínicas y radiológicas atípicas ocasionalmente. Presentamos un caso clínico radiológicamente peculiar, y realizamos una revisión de las novedades diagnósticas y terapéuticas que creemos son de interés para el neumólogo clínico.

A continuación se presenta el caso de un paciente natural de Ecuador, de 49 años de edad, sin antecedentes personales de interés, no fumador y sin contactos conocidos con pacientes afectos de tuberculosis. Consultó por un cuadro de tos crónica productiva de 10 meses de evolución, con esputos mucopurulentos y ocasionalmente hemoptoicos, además de intensa hiporexia y pérdida de 3 kg de peso. En la radiografía de tórax se apreciaban infiltrados pulmonares bilaterales con algunas imágenes pseudonodulares mal definidas, de predominio en los lóbulos superiores. Ingresó en régimen de aislamiento respiratorio con sospecha inicial de tuberculosis, siendo las baciloscopias de esputo negativas. Tras comprobar en la TAC de tórax la existencia de múltiples opacidades nodulares pulmonares bilaterales (fig. 1A y C), la mayoría

de ellas cavitadas, se realizó broncoscopia que no mostró hallazgos patológicos en la revisión bilateral exhaustiva. Se llevó a cabo un estudio citológico de las muestras de lavado broncoalveolar, diagnosticándose de adenocarcinoma de pulmón con patrón micropapilar. La delección del exón 19 fue positiva, mientras que el resto de las mutaciones estudiadas fueron negativas (L858R, T790M, G719A/C/S, exón 20, S768I y L861Q, ALK y ROS1). El paciente comenzó tratamiento con gefitinib, con buena respuesta clinicoradiológica a los 4 meses (fig. 1 B y D).

El adenocarcinoma es el tipo histológico más frecuente de cáncer de pulmón. En 2011 se publicó una nueva y necesaria clasificación de adenocarcinoma atendiendo a patrones distintos, con un pronóstico y manejo diferentes, tras un consenso en el cual participaron neumólogos, cirujanos torácicos, oncólogos, patólogos, biólogos moleculares y radiólogos<sup>1</sup>. En los años sucesivos se han ido introduciendo algunos cambios en esta clasificación, atendiendo a rasgos genéticos y de biología molecular. En la última revisión de la clasificación del adenocarcinoma pulmonar realizada en 2015 se distinguen 2 grupos: lesiones preinvasivas (hiperplasia adenomatosa atípica y adenocarcinoma in situ) y lesiones invasivas (adenocarcinoma mínimamente invasivo y adenocarcinoma invasivo)<sup>2,3</sup>.

El espectro de manifestaciones radiológicas del adenocarcinoma de pulmón es muy variable, desde lesiones subsólidas o sólidas a consolidaciones y masas que generalmente muestran una adecuada